International archives of allergy and immunology
-
Int. Arch. Allergy Immunol. · Jan 2021
Meta AnalysisDoes Asthma Increase the Mortality of Patients with COVID-19?: A Systematic Review and Meta-Analysis.
The purpose of this systematic review and meta-analysis was to explore the literature and collate data comparing the mortality of coronavirus disease 2019 (COVID-19) patients with and without asthma. The databases PubMed, Scopus, Embase, Google Scholar, and medRxiv.org were searched for studies comparing the clinical outcomes of asthmatic patients with those of nonasthmatic patients diagnosed with COVID-19. Mortality data were summarized using the Mantel-Haenszel OR with 95% CI in a random-effects model. ⋯ To conclude, preliminary data indicates that asthma as a comorbidity may not increase the mortality of COVID-19. Data on the influence of asthma on the risk of hospitalization, the duration of hospitalization, the requirement of ICU admission, and disease severity is still too limited to draw any strong conclusions. Further studies with a larger sample size are required to establish strong evidence.
-
Int. Arch. Allergy Immunol. · Jan 2021
Meta AnalysisCytokine Polymorphisms and Predisposition to Diabetic Nephropathy: A Meta-Analysis.
Cytokine polymorphismsmight influence the predisposition to diabetic nephropathy (DN), but the results of already published related studies are still controversial and ambiguous. ⋯ The meta-analysis results demonstrated that TNF-α -238 G/A, TNF-α -308 G/A, TNF-α -1031 C/T, IL-1A -889 C/T, IL-1B -511 C/Tand IL-18 -137 G/Cpolymorphisms might influence predisposition to DN in the overall pooled population. Moreover, TNF-α -308 G/A, IL-1B -511 C/T and IL-18 -137 G/C polymorphisms might influence predisposition to DN in Asians, whereas the IL-1B -511 C/T polymorphism might also influence predisposition to DN in Caucasians.
-
Int. Arch. Allergy Immunol. · Jan 2020
Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab.
New anti-IL-5 antibodies, mepolizumab and benralizumab, have recently been approved for severe asthma, sharing the same inclusion criteria. ⋯ This real-life study provides new insights for the personalized approach to severe asthma therapy. Although preliminary, the results indicate that besides eosinophils, KL-6 and sL-selectin are useful as biomarkers of early response that can also involve in the pathogenesis of severe asthma.
-
Int. Arch. Allergy Immunol. · Jan 2020
Multicenter Study Clinical Trial Observational StudyMepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
Mepolizumab is a monoclonal antibody against IL-5 for the treatment of severe eosinophilic asthma. The aim of the current study was to present a predesigned interim analysis of the data of patients who have completed 1 year of therapy with mepolizumab. ⋯ We have shown that in patients with severe eosinophilic asthma, 1 year of treatment with mepolizumab was safe, resulted in significant reduction of the annual exacerbation rate, reduction (or even discontinuation) of the needed dose of OCS, and improvements of asthma control and lung function.
-
Int. Arch. Allergy Immunol. · Jan 2020
ReviewJAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world. Understanding the Immunopathogenesis of COVID-19 is essential for interrupting viral infectivity and preventing aberrant immune responses before a vaccine can be developed. In this review, we provide the latest insights into the roles of angiotensin-converting enzyme II (ACE2) and Ang II receptor-1 (AT1-R) in this disease. ⋯ Furthermore, considering the common role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in AT1-R expressed on peripheral tissues and cytokine receptors on the surface of immune cells, potential targeting of this pathway using JAK inhibitors (JAKinibs) is suggested as a promising approach in patients with COVID-19 who are admitted to hospitals. In addition to antiviral therapy, potential ACE2- and AT1-R-inhibiting strategies, and other supportive care, we suggest other potential JAKinibs and novel anti-inflammatory combination therapies that affect the JAK-STAT pathway in patients with COVID-19. Since the combination of MTX and baricitinib leads to outstanding clinical outcomes, the addition of baricitinib to MTX might be a potential strategy.